Rheumatoid arthritis
Education on rheumatoid arthritis and Alpha-1 research hypotheses within the foundation autoimmune catalog.
Research status: Investigational / hypothesis
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between rheumatoid arthritis and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is rheumatoid arthritis?
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation, pain, stiffness, and swelling, often in a symmetric pattern. Diagnosis and treatment belong with rheumatology specialists and established guidelines. The Mark Egly Foundation does not replace rheumatology care.
Why RA appears in our autoimmune catalog
RA is one of the highest search volume autoimmune conditions. Mark Egly's patent names rheumatoid arthritis among inflammatory diseases that may relate to excess neutrophil elastase when Alpha-1 Antitrypsin (AAT) is insufficient. Browse the wider set on AATD and autoimmune diseases.
How this may relate to Alpha-1 (hypothesis)
The patent proposes that low AAT or AATD can allow destructive neutrophil enzymes to worsen tissue injury and inflammation. For RA, it suggests evaluating AAT status could be informative in some patients. That remains a research hypothesis, not a proven RA treatment path.
Established AATD facts still matter
If you have RA and also have unexplained lung disease, early emphysema, COPD, liver disease, or a family history of AATD, ask about AAT testing through established pathways:
Related pages
Sources and references
References checked July 26, 2026
- Alpha-1 antitrypsin deficiency (MedlinePlus Genetics (NIH))Research status: Established clinical knowledge
- American Thoracic Society / European Respiratory Society statements on lung disease (locate current AATD guidance) (American Thoracic Society)Research status: Established clinical knowledgeUse the current ATS/ERS AATD statements applicable to your practice.
- Method of Preventing and/or Treating a Plurality of Diseases (Mark Egly patent disclosure summary) (Mark Egly Foundation patent overview)Research status: Investigational / hypothesisPrimary source for Mark Egly research hypotheses. Not peer-reviewed clinical evidence. Confirm USPTO application number with counsel before citing externally.
Educational content only. Not a diagnosis or treatment plan. Work with your clinician for personal medical decisions.